Defibrotide Sodium Patent Expiration
Defibrotide Sodium is Used for treating hepatic veno-occlusive disease following hematopoietic stem cell transplantation in adults and pediatric patients. It was first introduced by Jazz Pharmaceuticals Inc
Defibrotide Sodium Patents
Given below is the list of patents protecting Defibrotide Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Defitelio | US11085043 | Euglobulin-based method for determining the biological activity of defibrotide | Jun 22, 2032 | Jazz Pharms Inc |
| Defitelio | US11236328 | Euglobulin-based method for determining the biological activity of defibrotide | Jun 22, 2032 | Jazz Pharms Inc |
| Defitelio | US11746348 | Euglobulin-based method for determining the biological activity of defibrotide | Jun 22, 2032 | Jazz Pharms Inc |
Defibrotide Sodium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List